These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 26608138)

  • 21. Carcinoembryonic antigen as a target for specific antitumor immunotherapy of head and neck cancer.
    Kass ES; Greiner JW; Kantor JA; Tsang KY; Guadagni F; Chen Z; Clark B; De Pascalis R; Schlom J; Van Waes C
    Cancer Res; 2002 Sep; 62(17):5049-57. PubMed ID: 12208760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamics of regulatory T cells (T
    Aggarwal S; Sharma SC; N Das S
    J Surg Oncol; 2017 Dec; 116(8):1103-1113. PubMed ID: 28833201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy with dendritic cells in an animal model of early pulmonary metastatic squamous cell carcinoma.
    Moon JH; Chung MK; Son YI
    Laryngoscope; 2012 Nov; 122(11):2442-6. PubMed ID: 22926978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma.
    Zolkind P; Dunn GP; Lin T; Griffith M; Griffith OL; Uppaluri R
    Oral Oncol; 2017 Aug; 71():169-176. PubMed ID: 27751760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA-based immunotherapy for HPV-associated head and neck cancer.
    Aggarwal C
    Immunotherapy; 2016 Oct; 8(10):1187-92. PubMed ID: 27605067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insights into Nanomedicine for Immunotherapeutics in Squamous Cell Carcinoma of the head and neck.
    Xu Q; Fang M; Zhu J; Dong H; Cao J; Yan L; Leonard F; Oppel F; Sudhoff H; Kaufmann AM; Albers AE; Qian X
    Int J Biol Sci; 2020; 16(14):2506-2517. PubMed ID: 32792853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effects of transfer factor on the number of circulating lymphocytes in patients with spinocellular carcinoma of the cervicofacial area].
    Mastromatteo V; Negri L; Pacchioni D; Calabrese F; Giacomasso S; Fazio M
    Boll Soc Ital Biol Sper; 1987 Nov; 63(11):1043-50. PubMed ID: 3454189
    [No Abstract]   [Full Text] [Related]  

  • 28. Human immunodeficiency virus-associated squamous cell carcinomas of the head and neck presenting as oral and primary intraosseous squamous cell carcinomas.
    Langford A; Langer R; Lobeck H; Stolpmann HJ; Pohle HD; Reichart P; Bier J
    Quintessence Int; 1995 Sep; 26(9):635-54. PubMed ID: 8602445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of levamisole immunotherapy as an adjuvant to radiotherapy in oral cancer. II. Lymphocyte subpopulations.
    Balaram P; Padmanabhan TK; Vasudevan DM
    Neoplasma; 1988; 35(2):235-42. PubMed ID: 3259681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options.
    Moskovitz JM; Moy J; Seiwert TY; Ferris RL
    Oncologist; 2017 Jun; 22(6):680-693. PubMed ID: 28507203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence for the changes of antitumor immune response during lymph node metastasis in head and neck squamous cell carcinoma.
    Kumagai K; Hamada Y; Gotoh A; Kobayashi H; Kawaguchi K; Horie A; Yamada H; Suzuki S; Suzuki R
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Sep; 110(3):341-50. PubMed ID: 20598595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Head and neck cancer immunotherapy: clinical evaluation.
    Leibowitz MS; Nayak JV; Ferris RL
    Curr Oncol Rep; 2008 Mar; 10(2):162-9. PubMed ID: 18377830
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The promise of immunotherapy in head and neck squamous cell carcinoma.
    Economopoulou P; Agelaki S; Perisanidis C; Giotakis EI; Psyrri A
    Ann Oncol; 2016 Sep; 27(9):1675-85. PubMed ID: 27380958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of a spontaneously arising murine squamous cell carcinoma (SCC VII) as a prerequisite for head and neck cancer immunotherapy.
    Khurana D; Martin EA; Kasperbauer JL; O'Malley BW; Salomao DR; Chen L; Strome SE
    Head Neck; 2001 Oct; 23(10):899-906. PubMed ID: 11592238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulatory T cells in oral squamous cell carcinoma.
    Liu S; Liu D; Li J; Zhang D; Chen Q
    J Oral Pathol Med; 2016 Oct; 45(9):635-639. PubMed ID: 27084296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor Immunology and Immunotherapy for Head and Neck Squamous Cell Carcinoma.
    Moskovitz JM; Ferris RL
    J Dent Res; 2018 Jun; 97(6):622-626. PubMed ID: 29489423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TILling head and neck cancer for cell therapy.
    Gottschalk S
    Cytotherapy; 2011 Aug; 13(7):772-3. PubMed ID: 21539499
    [No Abstract]   [Full Text] [Related]  

  • 38. Immune alterations and immunotherapy prospects in head and neck cancer.
    Varilla V; Atienza J; Dasanu CA
    Expert Opin Biol Ther; 2013 Sep; 13(9):1241-56. PubMed ID: 23789839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD-1 antibodies.
    Levingston CA; Young MR
    Int J Cancer; 2017 Apr; 140(7):1609-1619. PubMed ID: 27914100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.